Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Accumulated Expenses (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Accumulated Expenses for 11 consecutive years, with $807000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 180.21% to $807000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $807000.0, a 180.21% increase, with the full-year FY2024 number at $360000.0, up 5.57% from a year prior.
  • Accumulated Expenses was $807000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $1.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $2.2 million in Q3 2022 to a low of $38000.0 in Q3 2023.
  • A 5-year average of $670105.3 and a median of $442000.0 in 2025 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: soared 694.51% in 2021, then tumbled 98.25% in 2023.
  • NovaBay Pharmaceuticals' Accumulated Expenses stood at $443000.0 in 2021, then plummeted by 76.52% to $104000.0 in 2022, then soared by 227.88% to $341000.0 in 2023, then rose by 5.57% to $360000.0 in 2024, then skyrocketed by 124.17% to $807000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Accumulated Expenses are $807000.0 (Q3 2025), $1.0 million (Q2 2025), and $442000.0 (Q1 2025).